Latest

• Comparing expert representation on HTA advisory committees in Canada, the UK and Australia

  Are there expertise gaps on Canada’s HTA advisory committees? »

• Consequences of over-regulating the prices of new drugs in Canada

  Can the federal government preserve the availability of new medicines for Canadian patients while further depressing the prices of patented drugs? »

• Facts about the cost of patented drugs in Canada

  If governments are going to cite the cost of patented drugs to justify their policies, they should, at least, get the basic facts correct. »

• Costs without benefits for patients? Non-medical spending in Canada’s public health system

  Evidence suggests that billions of dollars are potentially being squandered annually on non-medical expenses without any demonstrable benefits for patients. »

• Does Canada need a Patented Medicine Prices Review Board?

  How will patients and taxpayers be impacted by the proposed changes to price regulations for new drugs? »

• The fiscal burden of provincial government health spending across Canada

  Healthcare spending is creating a fiscal emergency for provincial governments. Yet, the federal government has refused to exercise the one policy response that could help, without adding more pressure on the federal budget. »

• Societal cost savings from abuse deterrent formulations for prescription opioids in Canada

  Mandating abuse deterrent formulations for prescription opioids could reduce societal costs by $140 million to $4 billion annually. »

• Hospital spending across Canada’s Provinces, 1990-2014

  Where does your province rank for public spending on hospitals? »

• HTA decisions and access to mental health treatments in Canada’s public drug plans

  Waits to access caused by HTA decisions can be costly to patient health. »